What Bimeda does

Bimeda is a privately held global animal health company founded in Ireland in 1960 that manufactures, markets, and distributes veterinary pharmaceuticals and animal health products. The company operates 9 manufacturing facilities across 7 countries (including Ireland, the U.S., the U.K., Canada, Brazil, Argentina, China, and France), employs 1,200+ people globally, and reaches more than 80 countries across six continents through a network of authorized distributors, retail partners, and veterinary clinics. Its headquarters are in Dublin, Ireland, with the U.S. headquarters in Schaumburg, Illinois.

The core product portfolio is organized across five categories — ecto- and endo-parasiticides (Bimectin, Eprimectin, Doracide, MoxiSolv), water soluble antimicrobials (EnroMed, SpectoGard), injectables (BiloVet, Gamrozyne, BOVitalize Plus), nutritional products, and vaccines (Bimeda Biologicals) — serving three primary segments: livestock producers (cattle, swine, poultry), equine veterinarians and horse owners, and companion animal veterinarians. Bimeda's technology positioning centers on FDA-approved bioequivalent (ANADA) products that deliver clinically equivalent efficacy to pioneer-brand animal health products at competitive prices, supported by 8 R&D and 7 regulatory laboratories across four continents and proprietary formulations such as soluble glass trace element boluses (Cosecure Cattle) and Aspergillus oryzae-enhanced cattle supplements.

Bimeda generates revenue through one-time product sales via channel partners, including authorized animal health distributors, mass-market retail (Amazon, Chewy, Tractor Supply), and equine specialists (SmartPak, Dover Saddlery), with prescription products sold through veterinary clinics. The company is privately held with no disclosed parent, PE sponsor, or institutional investors, and has grown through a combination of organic product launches and strategic acquisitions over its 65-year history. Recent strategic activity is concentrated in the U.S. market, where Bimeda has launched or expanded at least six products or SKUs between November 2025 and May 2026 and added senior commercial leadership.

Name

Bimeda

Legal name

Bimeda Inc.

Website

https://bimedaus.com

Company type

Private

Founded year

1960

Operating status

Operating

Headcount range

11–50 employees

Short description

Bimeda is a privately held, Ireland-founded global animal health company that manufactures and distributes FDA-approved bioequivalent veterinary pharmaceuticals — parasiticides, antimicrobials, injectables, vaccines, and nutritionals — across 80+ countries, serving livestock producers, equine veterinarians, and companion animal practitioners through distributors and retail partners.

Ownership category

akta.pro rank

Headquarters

HQ city

Oak Brook

HQ country

United States

HQ region

North America

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Animal health product sales: Sale of veterinary pharmaceuticals and animal health products including parasiticides, antimicrobials, injectables, and nutritional supplements to livestock producers, equine practitioners, and companion animal veterinarians through distributor and retail channels

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Bimeda is a global manufacturer, marketer, and distributor of veterinary pharmaceuticals and animal health products. Its portfolio spans ecto- and endo-parasiticides, water soluble antimicrobials, injectables, nutritional products, vaccines, and trace element boluses serving livestock (cattle, swine, poultry), equine, and companion animal markets. Products are FDA-approved bioequivalents to pioneer brands, delivered through authorized distributors, veterinary clinics, and retail partners.

Product overview

Bimeda is a global animal health company offering a comprehensive portfolio of veterinary pharmaceuticals and animal health products organized across five key categories: ecto- and endo-parasiticides (Bimectin®, Eprimectin™, Doracide™, MoxiSolv™), water soluble antimicrobials (Tetroxy®, SpectoGard®, Lincomed®, EnroMed®), injectables (BiloVet®, Gamrozyne™, BOVitalize Plus™), and nutritional products. The product portfolio serves multiple animal species including horses (equine) with products like Gastrobim™ for gastric ulcers, Polyglycan® for joint support, and Bimectin® Paste for parasites; livestock (cattle and swine) with parasite control, antibiotics, and vaccines; poultry; and companion animals (dogs, cats). Bimeda also operates a custom vaccine manufacturing division (Bimeda Biologicals) and offers SecureCattle® for stress reduction in cattle. The company positions itself as a provider of both generic/bioequivalent products (approved under ANADA) and pioneer-quality formulations at competitive price points.

Differentiator

Problem solved

Functional benefit

Brands

• Gastrobim™: First and only FDA-approved bioequivalent to GastroGard® (omeprazole) for equine gastric ulcer treatment.
• BOVitalize Plus™
• Eprimectin™
• SecureCattle®
• Gamrozyne™
• Doracide™
• MoxiSolv™

Products and services

• Bimectin® Injection (ivermectin) Injectable parasiticide for cattle and swine providing effective treatment and control of a wide range of internal and external parasites including gastrointestinal roundworms, lungworms, grubs, sucking lice, and mange mites.
• Eprimectin™ Pour-On (eprinomectin) FDA-approved bioequivalent to Eprinex® pour-on for beef and dairy cattle including lactating dairy cattle. Provides broad-spectrum parasite control against 39 species and stages of internal and external parasites with zero milk and meat withdrawal time.
• BIMECTIN® Paste (ivermectin) Apple-flavored ivermectin paste anthelmintic and boticide for horses providing broadest spectrum activity against parasites and bots. Safe for horses of all ages including pregnant mares.
• BIMECTIN® Plus Injection Injectable parasiticide combining ivermectin and clorsulon for treatment and control of internal and external parasites including adult liver flukes in cattle.
• GASTROBIM™ (omeprazole) First and only FDA-approved bioequivalent to GastroGard® for treatment and prevention of recurrence of gastric ulcers in horses and foals 4 weeks of age and older. Apple-flavored formulation.
• BOVitalize Plus™ Oral nutritional supplement for beef and dairy cattle containing trace minerals (Selenium, Copper, Zinc), vitamins (A, E), and Aspergillus oryzae for enhanced rumen efficiency and digestive support.
• SecureCattle® Pour-on bovine appeasing substance (mBAS) solution designed to reduce the impact of stress on cattle and improve productivity. Available in 250mL (50-dose) and 1000mL (200-dose) sizes.
• MoxiSolv™ Injection FDA-approved bioequivalent to Cydectin® Injection containing 1% moxidectin for treatment and control of internal and external parasites in beef and non-lactating dairy cattle.
• Doracide™ (doramectin topical solution) Bioequivalent to Dectomax® Pour-On providing weatherproof parasite control for cattle. Controls 33 types of internal and external parasites with single dose including 77 days protection against biting cattle louse.
• EnroMed® 100 (enrofloxacin) FDA-approved bioequivalent to Baytril 100® sterile injectable fluoroquinolone for treatment and control of bovine respiratory disease (BRD) and swine respiratory disease (SRD).
• Gamrozyne™ (gamithromycin) First and only FDA-approved bioequivalent to Zactran® for treatment and control of Bovine Respiratory Disease (BRD). Reaches target tissue in 30 minutes with 10 days of treatment duration.
• BiloVet® (tylosin injection) Versatile, fast-acting antibiotic containing 200mg tylosin per mL for treatment of bovine respiratory complex, foot rot, calf diphtheria, metritis in cattle, and arthritis, pneumonia, erysipelas, dysentery in swine.
• SpectoGard® Sterile Solution (spectinomycin sulfate) First and only FDA-approved bioequivalent to Adspec® for treatment of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni.
• Cosecure Cattle (soluble glass trace element bolus) World's only soluble glass trace element bolus manufactured at Bimeda's Denbigh, Wales facility. Provides controlled, constant rate delivery of trace elements for health and fertility of ruminants. UK and Ireland's only medicinal (POM-VPS, LM) multiple trace element bolus.
• Polyglycan® (hyaluronic acid + chondroitin sulfates + N-acetyl-D-glucosamine) Joint support supplement for horses available in multiple formulations including Polyglycan®-SA, Polyglycan®-HV, and Polyglycan® Sterile Solution for IV/intra-articular use.
• Tandem™ Oral Joint support supplement for horses containing hyaluronic acid, chondroitin sulfate, glucosamine and MSM in granule form for oral administration.
• Detomequin® (detomidine hydrochloride) Sedative and analgesic for horses and yearlings to facilitate minor surgical and diagnostic procedures. Bioequivalent to Dormosedan® approved under ANADA #200-674.
• Custom Vaccines (autogenous vaccines) Custom autogenous vaccine program through Bimeda Biologicals for customized vaccination solutions tailored to specific herd health challenges.
• Bimeda Biologicals (commercial cattle vaccines) Commercial cattle vaccine portfolio including Myco-Bac® (killed Mycoplasma bovis vaccine), Pro-Bac™ Vaccines (killed bacterial vaccines), and Stimulator® Vaccines (modified live virus vaccines). Also includes custom vaccine manufacturing capabilities.

Quantifiable outcome

• Gastrobim became fastest-growing omeprazole product in Canada and Europe since 2022/2024 launch
• +1 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Generic Animal Drug Alliance (GADA)coreOthersBimeda is a proud member of GADA, an independent professional trade association representing the interests of generic animal drug companies. GADA supports education of veterinarians and the general public on generic drug safety, quality process, and FDA approval.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Elanco Animal Health: Major animal health pharma player in livestock and companion animals. Overlaps with Bimeda in parasiticides, BRD therapeutics, and equine segments, competing for distributor and veterinarian mindshare.
• Merck Animal Health (MSD Animal Health): Global animal health division of Merck/MSD, with deep livestock and companion animal portfolios. Competes with Bimeda across vaccines, anti-infectives, and parasiticides worldwide.
• Zoetis: Largest pure-play animal health company globally. Direct overlap with Bimeda across parasiticides, vaccines, anti-infectives, and equine products; Bimeda's bioequivalents target Zoetis's pioneer brands like GastroGard and Dectomax.
• Boehringer Ingelheim Animal Health: Top-three global animal health player with broad livestock, companion, and equine portfolios. Bimeda's Eprimectin (bioequivalent to Eprinex) and other parasiticide products directly compete with Boehringer's pioneer franchises.

Direct peers

• Vetoquinol: Independent French-headquartered animal health company focused on livestock and companion animals. Comparable to Bimeda in size, geographic footprint, and portfolio composition across parasiticides and specialty therapeutics.
• Virbac: Independent global animal health company specializing in livestock and companion animal pharmaceuticals. Closely comparable to Bimeda in size, distribution model, and product breadth; both target veterinarians and livestock producers with parasiticides, anti-infectives, and specialty products.
• Norbrook Laboratories: Privately held UK/Irish-headquartered animal health manufacturer of generic veterinary pharmaceuticals. Closely comparable to Bimeda in manufacturing footprint, bioequivalent focus, and livestock/companion product mix.
• Ceva Santé Animale: Privately held global animal health company with strong livestock, poultry, and companion portfolios. Highly comparable to Bimeda in scale, ownership structure (private), and focus on multi-species veterinary pharmaceuticals.
• Phibro Animal Health: Global animal health and nutrition company serving livestock and companion markets. Comparable to Bimeda in targeting livestock producers with parasiticides, anti-infectives, and nutritional products.

Emerging players

• Dechra Pharmaceuticals: Specialty animal health pharma company with strength in companion animal endocrinology, dermatology, and equine. Bimeda's equine portfolio (Gastrobim, Polyglycan) overlaps with Dechra's specialty veterinary segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bimeda-inc

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bimeda